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ABSTRACT 
Objective: The purpose of this study is to investigate the effect of xanthan gum and lactose on the physical and release 
properties of 25-mg and 75-mg indomethacin tablets containing polyethylene glycol (PEG) prepared by mold technique. Method: 
The physical and drug release characteristics of developed matrix tablet were studied. Least square fitting the experimental 
dissolution data to the mathematical expressions (power law, first order, Higuchi’s and zero order) was carried out. Results: 
Because of the more completion dissolution of drug in PEG matrix, the drug release from the lower-drug loading tablet was 
faster than the higher-drug loading tablet. An addition of xanthan gum could sustain the drug release whereas an addition of 
lactose diminished the drug dissolution. From curve fitting, most drug release profiles were primarily as Fickian diffusion. 
Conclusion: Amount of indomethacin played an important role on the drug released from PEG matrix consisting xanthan gum 
and lactose prepared with fusion and mold technique. Xanthan gum and lactose also affected the physical and release 
characteristics of these investigated indomethacin tablets.  
Keywords: Characterization, drug, release, mold tablet, hydroxypropyl methylcellulose, polyethylene glycol  
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Introduction
§Hydrophilic polymeric matrix systems are widely used 
to modulate the controlled release of drug substances 
because of their versatility, effectiveness, and low 
production cost. Typically, the drug can be incorporated 
into the polymer matrix in form of particle or molecular 
dispersion. While the matrix containing a swellable 
glassy polymer comes into contact with a solvent, a 
progressive alteration from the glassy to the rubbery 
state leads to a swelling process. For matrix system, 
drug is often released by diffusion, because a sort of 
receding drug boundary comes to exist within the 
system.1 The thickness of this hydrate layer determines 
                                                 
§ 14th year of Srinakharinwirot Journal of Pharmaceutical Science 
the diffusion of the drug molecules through the polymer 
mass into the dissolution fluid. Available hydrophilic 
polymers include hydroxypropyl methylcellulose (HPMC), 
hydroxypropylcellulose (HPC), hydroxyethylcellulose 
(HEC), xanthan gum, sodium alginate, poly (ethylene 
oxide) and crosslinked homopolymers and copolymers of 
acrylic acid. 
Practically, pharmaceutical tablet is prepared by 
compression method. Some special tablet such as, 
orodispersible tablet, could be prepared by freeze drying. 
Melt extrusion has been recently reported as the 
procedure to produce the drug matrix system for 
enhancing or retarding the drug release. The main 
excipient employed for this system should be molten at 
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elevated temperature and could set up as solid matter at 
room temperature. Polyethylene glycols (PEGs) are 
widely used in a variety of pharmaceutical formulations 
including parenteral, topical, ophthalmic, oral and rectal 
preparations.2 Polyethylene glycols can also be used to 
enhance the aqueous solubility characteristics of poorly 
water-soluble compounds.3 Particularly, PEG 4000 or 
6000 has been employed as a carrier for increasing the 
dissolution rate of several poorly water–soluble drugs, 
such as itraconazole4, diclofenac5, prednisolone6 and 
rofecoxib6. All grades of polyethylene glycol are soluble 
in water and miscible in all proportions with other 
polyethylene glycol. PEG has potentially been utilized as 
matrix component prepared with fusion and mold 
method.   
Indomethacin is non-steroidal anti-inflammatory agent 
with anti-pyretic and analgesic properties. It is a 
nonselective inhibitor of cyclooxygenase (COX) 1 and 2, 
enzymes that participate in prostaglandin synthesis from 
arachidonic acid. It has been used in the symptomatic 
management of painful and inflammatory conditions. It is 
used in musculoskeletal and joint disorders including 
ankylosing spondylitis, osteoarthritis, rheumatoid arthritis 
and acute gouty arthritis. Usual initial dose by mouth in 
musculoskeletal and joint disorder is 25 mg two or three 
times daily with food. To alleviate night pain and morning 
stiffness, 100 mg may be administered by mouth, or 
rectally as a suppository. In acute gouty arthritis a 
suggested dose is 50 mg three times daily and in 
dysmenorrheal up to 75 mg daily has been suggested. 
Indomethacin is practically insoluble in water, soluble 1 in 
50 of ethanol, 1 in 30 of chloroform, and 1 in 40 to 45 of 
ether, and soluble in acetone.7 Because of its low water 
solubility, therefore indomethacin is used as a model 
drug in the study. 
Xanthan gum is a heteropolysaccharide with a primary 
structure consisting of repeated pentasaccharide units 
formed by two glucose units, two mannose units, and 
one glucuronic acid unit, in a molar ratio of 2.8:2.0:2.0. 
Its main chain consists of β-D-glucose units linked at 
positions 1 and 4. The chemical structure of the main 
chain is identical to that of cellulose. Trisaccharide side 
chains contain a D-glucuronic acid unit between two D-
mannose units linked at the O-3 position of every other 
glucose residue in the main chain. Approximately one-
half of the terminal D-mannose contains a pyruvic acid 
residue linked via keto group to the 4 and 6 positions, 
with an unknown distribution. D-Mannose unit linked to 
the main chain contains an acetyl group at position O-6. 
The presence of acetic and pyruvic acids produces an 
anionic polysaccharide type.8 Because of its properties in 
thickening aqueous solutions, as a dispersing agent, and 
stabilizer of emulsions and suspensions, xanthan gum is 
used in pharmaceutical formulations, cosmetics, and 
agricultural products.  
The combination of PEG with hydrophilic polymer such 
as xanthan gum should be used to develop into the 
system comprising both the drug dissolution 
enhancement property together with the prolongation of 
the drug release. The aim of this study was to investigate 
the effect of xanthan gum and lactose on the physical 
integrities and release properties of 25-mg and 75-mg 
indomethacin tablets containing PEG prepared by fusion 
and mold technique.  
 
Materials and Methods  
Materials 
Indomethacin (Batch No. 050814, China National 
Chemical Imp. Exp., China) was used as received. 
Polyethylene glycol 4000 (lot no. 504907) and 
polyethylene glycol 400 (lot no. PO76049) were 
purchased from P.C. Drug Center Co., Ltd., Thailand. Di-
sodium hydrogen orthophosphate (lot no. 405300, Ajax 
Finechem, Australia), hydrochloric acid (lot no. E23W60, 
J.T. Baker, USA), potassium dihydrogen orthophosphate 
(lot no. E23W60, Ajax Finechem, Australia), sodium 
chloride (lot no. AF 407256, Ajax Finechem, Australia), 
sodium hydroxide (lot no. AF 310204, Ajax Finechem, 
Australia) were used to prepare the dissolution fluids. 
Xanthan gum (Xantural 75®) (lot no. 01-100, CP Kelco 
U.S., Inc. USA.). Lactose (lot no. 080200 A 9249, 
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Auckland, New Zealand) was passed the 80 mesh sieve 
before use. 
 
Preparation of Tablet by Mold Technique  
Tablets containing 25-mg or 75-mg indomethacin, 
PEG4000:PEG400 (7:3) and different amount of xanthan 
gum (0, 5, 10, 15, 20 and 25%w/w) were prepared with 
the melting and mold technique. The tablet was prepared 
by melting PEG 4000 on the water bath and mixed with 
PEG 400, drug and xanthan gum, respectively, and then 
the mixtures were poured into the stainless steel mold 
with diameter of 12 mm (Figure 1). The effect of lactose 
on the physical properties and drug release from matrix 
tablet was investigated. Tablets of about 0.87 g 
containing 75-mg of indomethacin, 5% xanthan gum and 
different amount of lactose (0, 15, 25, 35, 45 and 
55%w/w) in 7:3 PEG4000:PEG400 were prepared with 
the melting and mold technique using the stainless steel 
mold with diameter of 12 mm. as method described 
above.  
 
Evaluation of Physical Properties of Prepared 
Tablet 
The hardness of the tablets was determined using a 
hardness tester (Pharmatest, USA). The tablet thickness 
and diameter were measured using a thickness tester 
(Teclock, Japan). A test of drug release was undertaken 
in 900 mL phosphate buffer pH 6.2 using a dissolution 
apparatus (Erweka DT 70, Germany) with the basket 
method at 100 rpm. Samples were collected at specific 
time intervals and assayed by a UV-Vis spectro-
photometer (Perkin-Elmer, Germany) at a wavelength of 
323 nm. During the drug release studies, the tablets 
were observed for physical integrity. Drug release from 
these tablets was compared to capsule containing only 
75-mg indomethacin powder.  
 
Dissolution Profile Fitting 
Least square fitting the experimental dissolution data 
(cumulative drug release > 5% and up to 80%) to the 
mathematical equations (power law, first order, Higuchi’s 
and zero order) was carried out using a nonlinear 
computer programme, Scientist for Windows, version 2.1 
(MicroMath Scientific Software, Salt Lake City, UT, USA). 
The coefficient of determination (r2) was used to indicate 
the degree of curve fitting. Goodness-of-fit was also 
evaluated using the Model Selection Criterion (msc)9, 
given below.  
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Where Yobsi and Ycali are observed and calculated 
values of the i-th point, respectively, and wi is the weight 
that applies to the i-th point, n is number of points and p 
is number of parameters. 
 
Results and Discussion  
The Physical Properties of Matrix Tablets 
The hardness of tablets increased as the amount of 
xanthan gum or lactose was increased (Tables 1-4). By 
comparison, the hardness of tablets containing higher 
amount of indomethacin was higher than that of tablets 
containing lower amount of indomethacin. All investigated 
tablets could be easily removed from the stainless steel 
mold. The yellowish shade of tablets diminished as the 
amount of xanthan gum or lactose was increased. 
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Table 1 Physical integrities of 25-mg indomethacin tablet containing 70:30 PEG4000:PEG400 and different amount of 
xanthan gum.  
Physical Properties Amount of 
xanthan gum (%) Weight (g)* (n = 20) Thickness (mm)* (n = 10) Diameter (mm)* (n = 10) Hardness (Newton)* (n = 10) 
0 0.8621 ± 0.0138 6.81 ± 0.22 11.96 ± 0.04 12.42 ± 1.08 
5 0.8620 ± 0.0091 6.73 ± 0.18 12.05 ± 0.06 12.72 ± 0.62 
10 0.8639 ± 0.0119 6.72 ± 0.17 12.04 ± 0.02 13.71 ± 1.33 
15 0.8689 ± 0.0082 6.75 ± 0.11 12.03 ± 0.03 15.61 ± 0.97 
20 0.8730 ± 0.026 6.80 ± 0.13 12.01 ± 0.03 16.03 ± 1.25 
25 0.8781 ± 0.0201 6.76 ± 0.12 12.03 ± 0.05 16.92 ± 1.03 
* Presented as mean ± S.D.   
 
Table 2 Physical integrities of 75-mg indomethacin tablet containing 70:30 PEG4000:PEG400 and different amount of 
xanthan gum. 
Physical Properties Amount of 
xanthan gum (%) Weight (g)* (n = 20) Thickness (mm)* (n = 10) Diameter (mm)* (n = 10) Hardness (Newton)* (n = 10) 
0 0.8551 ± 0.0146 6.73 ± 0.21 11.91 ± 0.03 14.62 ± 1.75 
5 0.8709 ± 0.0089 6.82 ± 0.22 12.03 ± 0.02 15.22 ± 1.65 
10 0.8685 ± 0.0098 6.73 ± 0.22 12.02 ± 0.03 16.68 ± 1.73 
15 0.8739 ± 0.0098 6.65 ± 0.21 12.00 ± 0.02 17.64 ± 1.78 
20 0.8810 ± 0.0228 6.82 ± 0.19 12.03 ± 0.02 18.43 ± 1.78 
25 0.8762 ± 0.0151 6.72 ± 0.19 12.02 ± 0.02 18.95 ± 1.83 
 
Table 3 Physical integrities of 25-mg indomethacin tablets containing 5%w/w xanthan gum and different amount of 
lactose in 70:30 PEG4000:PEG400.  
Physical Properties Amount of 
lactose (%) Weight (g)* (n=20) Thickness (mm)* (n=10) Diameter (mm)*  n=10) Hardness (Newton)* (n=10) 
15 0.8674 ± 0.0203 6.72 ± 0.12 12.03 ± 0.05 18.62 ± 2.19 
25 0.8693 ± 0.0112 6.76 ± 0.11 12.02 ± 0.03 23.21 ± 2.31 
35 0.8701 ± 0.0187 6.78 ± 0.29 12.04 ± 0.06 30.41 ± 2.16 
45 0.8729 ± 0.0093 6.80 ± 0.20 12.02 ± 0.04 34.46 ± 2.02 
55 0.8795 ± 0.0209 6.77 ± 0.18 12.02 ± 0.07 41.80 ± 3.66 
* Presented as mean ± S.D.  
 
Table 4 Physical integrities of 75-mg indomethacin tablets containing 5%w/w xanthan gum and different amount of 
lactose in 70:30 PEG4000:PEG400.   
Physical Properties Amount of 
lactose (%) Weight (g)* (n=20) Thickness (mm)* (n=10) Diameter (mm)* (n=10) Hardness (Newton)* (n=10) 
15 0.8834 ± 0.0234 6.78 ± 0.19 12.05 ± 0.02 20.30 ± 4.67 
25 0.8789 ± 0.0312 6.82 ± 0.31 12.08 ± 0.02 26.40 ± 5.75 
35 0.8704 ± 0.0237 6.75 ± 0.25 12.06 ± 0.02 34.50 ± 3.27 
45 0.8756 ± 0.0187 6.82 ± 0.26 12.04 ± 0.02 37.70 ± 2.92 
55 0.8821 ± 0.0256 6.79 ± 0.21 12.05 ± 0.02 46.70 ± 3.17 
* Presented as mean ± S.D.  
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In Vitro Drug Release Studies 
The dissolution of indomethacin from tablets containing 
different amounts of xanthan gum is shown in Figure 1. 
Apparently, the drug release from tablet without an 
addition of xanthan gum was faster than that containing 
xanthan gum because the former tablet contained PEG 
as a carrier for increasing the solubility of indomethacin. 
Polyethylene glycols (PEGs) are one of the most widely 
used carriers to prepare solid dispersions due to their 
low melting point and their ability to provide the 
hydrophilic environment to enhance the drug solubility.2 
An enhancement of dissolution rate of hydrocortisone 
and prednisolone has been reported by means of the 
fusion method, using sorbitol, sucrose, or PEG 6000 as 
carrier. The carriers were melted at elevated temperature 
and the drugs were dissolved in molten carriers.10,11 To 
confirm this result, drug release form tablet prepared by 
solid dispersion method was faster than that from 
capsule containing only indomethacin.   
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Figure Drug release profiles of indomethacin in 25-mg tablet (A) and 75-mg tablet (B) containing 
different amount of xanthan gum and capsule in phosphate buffer pH 6.2 (n = 3).  
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Drug release from tablet containing 5% xanthan gum 
was faster than that of tablets containing 10%, 15%, 
20%, 25% xanthan gum and capsule, respectively. High 
swelling capacity and gel formation of xanthan gum could 
retard the release of dissolved drug from the matrix. 
Relationship between drug release rate and polymer 
concentration was previously reported by Fu et al., 
(2004).12 As also described by Ghimire et al. (2007)13, 
water insoluble drug released from matrix tablets and 
erosion properties of matrix tablet was found to be 
dependent upon the polymer concentration; however no 
direct correlation was found between erosion profile and 
drug release. Drug release from capsule containing only 
powder of 75-mg indomethacin was slower than that of 
all tablets containing xanthan gum because indomethacin 
powder in capsule is a poorly water-soluble drug (5 
µg/mL).4 
The viscosity of xanthan solutions strongly increases 
with increasing concentration of the polymer. The 
behavior is attributable to the intermolecular interaction 
or entanglement, increasing the effective macromolecule 
dimensions and molecular weight. The presence of salts 
in solution influences the xanthan viscosity.14,15 The drug 
release from capsule was only about 20% drug release 
at 8 hours. Therefore, this solid dispersion system could 
enhance the release of indomethacin when compared 
with that from 75-mg indomethacin capsule. Xanthan 
gum played the important role by rapid hydration after 
contact to dissolution fluid and subsequently to form gel 
around the tablet and the dissolved drug molecules 
gradually diffused from the tablet through the developed 
gel layer into the dissolution fluid. Therefore the 
dissolved drug molecules inducing with carrier could 
prolong release by an addition of xanthan gum in the 
matrix system.16 
The drug dissolution from tablet containing lower drug 
loading (25-mg) was faster than that of tablet containing 
higher drug loading (75-mg) as shown in Figures 1 and 
2. This indicated that the more freely soluble drug from 
the first case owing to its higher amount of carrier to 
induce the drug dissolution and the dissolved drug could 
diffuse through the polymeric gel layer according to the 
concentration gradient more easily than the later system. 
After addition of different amount of lactose into xanthan 
gum matrix, the percentage of drug release was lower as 
presented in Figure 2. The drug release decrement for 
tablet containing the increment amount of lactose was 
due to a diminishment of drug carrier amount. Similar 
result has been mentioned previously for utilization a ram 
extruder to prepare directly a fast release dosage form of 
carbamazepine with uniform shape and density, 
comprising polyethylene glycol 4000 (PEG) as a low 
melting binder which an addition of lactose in this system 
reduced the dissolution rate.  
 
Analysis of the drug release data  
To analyze the in vitro release data, the curve fitting of 
drug dissolution profiles to various kinetic models was 
carried out to describe the release kinetics. Large value 
of the coefficient of determination (r2) or model selection 
criteria (MSC) indicated a superiority of the dissolution 
profile fitting to mathematical equations. Kinetics of drug 
release from the developed matrices was analyzed using 
the power law expression. This equation (an empirical 
equation) gained popularity for analysis of release data.17 
The n value from power law is the diffusional exponent 
which characterizes the transport mechanism of the drug. 
The transport mechanisms are classified based on the 
value that n assumes. For a cylinder, the drug transport 
mechanism is by Fickian diffusion when n = 0.45. If 0.45 
< n < 0.89, it indicates anomalous (non-Fickian) 
transport. For values of n = 0.89, case II or zero order 
release kinetics is indicated. Case II relates to polymer 
relaxation, while non-Fickian release is described by two 
mechanisms; the coupling of drug diffusion and polymer 
relaxation.17,18 
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Figure 2 Drug release profiles of indomethacin in 25-mg tablet (A) and 75-mg tablet (B) containing 
5% xanthan gum and different amount of lactose in phosphate buffer pH 6.2 (n = 3).  
 
 
The r2 from curve fitting to power law equation was in 
a range of 0.9771 to 0.9989 and msc was in a range of 
2.78 to 6.23 (Tables 5, 7, 9 and 11). From curve fitting, 
the most of drug release from 25-mg and 75-mg 
indomethacin tablets containing different amount of 
xanthan gum were fitted well with Higuchi’s model since 
r2 and msc from their curve fitting were higher than first-
order model and zero order curve fitting. The n value of 
the most release profile fitting was also close to 0.45 
which indicated the Fickian drug release behavior (Table 
6, 8, 10, 12). Near zero-order release was achieved for 
the drug release from 75-mg indomethacin tablets 
containing high amount of lactose (Table 12) hence they 
exhibited a Case-II transport.19 These results were in 
agreement with the ones published that established 
correlation among the swelling, erosion and drug release 
in hydrophilic matrices elaborated from natural gums as 
xanthan, karaia and locust bean gum.20 However, it could 
not specify the tendency of release kinetic of drug 
release from tablets containing 25-mg indomethacin 
tablet containing lactose. This different release 
mechanism might be due to the limitation of drug 
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solubilization in different amount of carrier as mentioned 
previously. ND means "not determined" for cumulative 
drug release which was less than 5% or more than 90% 
and that data points were not substantial enough to be 
determined by curve fitting. Practically, all the kinetic 
models, other than the zero order, fitted well at early time 
periods. Therefore, modeling analysis was carried out by 
fitting the dissolution data until the time 90% of the drug 
released.   
 
 
 
Table 5 Comparison of degree of goodness-of-fit from curve fitting of drug dissolution from 25-mg indomethacin tablet 
containing different amount of xanthan gum in 70:30 PEG4000:PEG400 system in phosphate buffer pH 6.2 
to different release models.  
Power law First order Higuchi’s Zero order Amount of xanthan gum (%) 
r2 msc r2 msc r2 msc r2 msc 
0 ND ND ND ND ND ND ND ND 
5 ND ND ND ND ND ND ND ND 
10 0.9965 5.18 0.9774 3.48 0.9857 3.94 0.9163 2.17 
15 0.9898 4.04 0.9570 2.78 0.9772 3.42 0.9060 2.00 
20 0.9973 5.45 0.9956 5.11 0.9904 4.34 0.9845 3.86 
25 0.9974 5.32 0.9921 4.44 0.9953 4.95 0.9857 3.85 
ND = not determined.  
 
 
Table 6 Estimate parameter from curve fitting of drug dissolution from 25-mg indomethacin tablet containing different 
amount of xanthan gum in 70:30 PEG4000:PEG400 system in phosphate buffer pH 6.2 to power law 
expression.  
Amount of xanthan gum (%) k ± sd*10-1 tl ± sd (min) n ± sd 
0 ND ND ND 
5 ND ND ND 
10 0.7053 ± 0.0525 1.78 ± 1.15 0.41 ± 0.01 
15 0.6058 ± 0.0085 26.28 ± 2.18 0.39 ± 0.03 
20 0.1040 ± 0.0202 -7.38 ± 7.53 0.63 ± 0.03 
25 0.0895 ± 0.0236 27.65 ± 12.97 0.58 ± 0.04 
ND = not determined.   
 
 
Table 7 Comparison of degree of goodness-of-fit from curve fitting of drug dissolution from 75-mg indomethacin tablet 
containing different amount of xanthan gum in 70:30 PEG4000:PEG400 system in phosphate buffer pH 6.2 
to different release models.   
Power law First order Higuchi’s Zero order Amount of xanthan gum (%) 
r2 msc r2 msc r2 msc r2 msc 
0 ND ND ND ND ND ND ND ND 
5 0.9985 5.95 0.8996 1.90 0.8560 1.54 0.7572 1.02 
10 0.9944 4.73 0.9519 2.73 0.9896 4.26 0.9391 2.49 
15 0.9816 3.45 0.8806 1.76 0.9449 2.54 0.8762 1.73 
20 0.9955 5.46 0.8987 1.85 0.9597 2.81 0.9276 2.23 
25 0.9913 4.98 0.8935 1.80 0.9562 2.68 0.9166 2.04 
ND = not determined.  
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Table 8 Estimate parameter from curve fitting of drug dissolution from 75-mg indomethacin tablet containing different 
amount of xanthan gum in 70:30 PEG4000:PEG400 system in phosphate buffer pH 6.2 to power law 
expression.  
Amount of xanthan gum (%) k ± sd*10-1 tl ± sd (min) n ± sd 
0 ND ND ND 
5 0.0098 ± 0.0011 64.39 ± 4.23 0.51 ± 0.02 
10 0.0187 ± 0.0025 14.64 ± 4.70 0.42 ± 0.02 
15 0.0225 ± 0.0041 46.32 ± 7.05 0.32 ± 0.03 
20 0.0238 ± 0.0072 28.21 ± 9.38 0.43 ± 0.05 
25 0.0162 ± 0.0091 15.94 ± 62.13 0.44 ± 0.11 
ND = not determined.  
 
 
Table 9 Comparison of degree of goodness-of-fit from curve fitting of drug dissolution from 25-mg indomethacin tablet, 
5% xanthan gum containing different amount of lactose in 70:30 PEG4000:PEG400 system in phosphate 
buffer pH 6.2 to different release models. 
Power law First order Higuchi’s Zero order Amount of lactose (%) 
r2 msc r2 msc r2 msc r2 msc 
0 0.9977 5.07 0.9475 2.28 0.8922 1.56 0.7878 0.88 
15 0.9964 4.88 0.9903 4.13 0.9869 3.84 0.9172 1.99 
25 0.9892 3.98 0.9559 2.76 0.9289 2.28 0.9877 4.03 
35 0.9974 5.34 0.9959 5.11 0.9901 4.21 0.9872 3.96 
45 0.9771 2.92 0.9738 3.07 0.9751 3.12 0.9671 2.84 
55 0.9772 2.78 0.9655 2.70 0.9771 3.11 0.9558 2.45 
 
 
Table 10 Estimate parameter from curve fitting of drug dissolution from 25-mg indomethacin tablet, 5% xanthan gum 
containing different amount of lactose in 70:30 PEG4000:PEG400 system in phosphate buffer pH 6.2 to 
power law expression. 
Amount of lactose (%) k ± sd*10-1 tl ± sd (min) n ± sd 
0 2.9082 ± 0.1673 4.68 ± 0.13 0.24 ± 0.01 
15 1.0766 ± 0.1071 2.52 ± 0.92 0.41 ± 0.02 
25 0.0032 ± 0.0057 -96.17 ± 63.62 1.24 ± 0.26 
35 1.0314 ± 0.0256 45.85 ± 9.91 0.64 ± 0.04 
45 0.0982 ± 0.1209 116.40 ± 52.77 0.59 ± 0.20 
55 0.1370 ± 0.1402 170.58 ± 36.35 0.52 ± 0.17 
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Table 11 Comparison of degree of goodness-of-fit from curve fitting of drug dissolution from 75-mg indomethacin 
tablet, 5% xanthan gum containing different amount of lactose in 70:30 PEG4000:PEG400 system in 
phosphate buffer pH 6.2 to different release models. 
Power law First order Higuchi’s Zero order Amount of lactose (%) 
r2 msc r2 msc r2 msc r2 msc 
0 0.9985 3.10 0.8996 1.90 0.8560 1.54 0.7572 1.02 
15 0.9898 4.13 0.9577 3.10 0.9597 3.26 0.9667 3.10 
25 0.9969 5.27 0.9956 5.12 0.9549 2.77 0.9965 5.33 
35 0.9989 6.23 0.9976 5.65 0.9301 2.30 0.9988 6.37 
45 0.9959 5.27 0.9981 5.87 0.9641 2.93 0.9991 6.64 
55 0.9897 3.83 0.9030 1.83 0.9886 3.97 0.9890 4.52 
 
 
Table 12 Estimate parameter from curve fitting of drug dissolution from 75-mg indomethacin tablet, 5% xanthan gum 
containing different amount of lactose in 70:30 PEG4000:PEG400 system in phosphate buffer pH 6.2 to 
power law expression.   
Amount of lactose (%) k ± sd*10-1 tl ± sd (min) n ± sd 
0 0.0098 ± 0.0011 64.39 ± 4.23 0.51 ± 0.02 
15 0.0167 ± 0.0042 9.22 ± 8.78 0.52 ± 0.04 
25 0.0011 ± 0.0005 -37.21 ± 18.46 0.92 ± 0.07 
35 0.0008 ± 0.0002 -8.46 ± 10.99 0.97 ± 0.05 
45 0.0032 ± 0.0012 55.32 ± 10.12 0.91 ± 0.05 
55 0.0050 ± 0.0038 70.33 ± 39.05 0.58 ± 0.12 
 
 
Conclusion  
The fusion and mold technique was used to develop 
the indomethacin tablet in PEG matrix. Amount of poorly 
water-soluble drug such as, indomethacin, played an 
important role on the drug released from PEG matrix 
containing xanthan gum and lactose. Because of the 
more completion dissolution of drug in PEG matrix, the 
drug release from the lower-drug loading tablet was 
faster than the higher-drug loading tablet. An addition of 
xanthan gum could sustain the drug release whereas an 
addition of lactose diminished the drug dissolution.  
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